Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Pakistan Institute of Living and Learning
- Target Recruit Count
- 265
- Registration Number
- NCT02703363
- Locations
- 🇵🇰
Karwan-e-Hayat, Karachi, Sindh, Pakistan
🇵🇰Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan
🇵🇰Dow University of Health Sciences, Karachi, Sindh, Pakistan
Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- TRB Chemedica International SA
- Target Recruit Count
- 380
- Registration Number
- NCT02688400
- Locations
- 🇨🇿
Affidea Praha, s.r.o., Prague, Czechia
🇪🇸Rheumatology Hospital Universitario A Coruna, A Coruna, Spain
🇧🇪Institut Médical Spécialisé - Centre DISCCA, Hornu, Belgium
Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries
- Conditions
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Canadian Department of National Defense
- Target Recruit Count
- 168
- Registration Number
- NCT02667730
- Locations
- 🇨🇦
2 Fd Amb medical clinic, Petawawa, Ontario, Canada
Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Zhixiang Huang
- Target Recruit Count
- 100
- Registration Number
- NCT02638896
Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 18
- Registration Number
- NCT02602509
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 60
- Registration Number
- NCT02574728
- Locations
- 🇺🇸
Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States
🇺🇸Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States
The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Changjie Huang
- Target Recruit Count
- 120
- Registration Number
- NCT02537925
- Locations
- 🇨🇳
The third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Effect of AKB-6548 on the Pharmacokinetics of Celecoxib
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT02502500
Variability in Response to Non-steroidal Anti-inflammatory Drugs
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 16
- Registration Number
- NCT02502006
- Locations
- 🇺🇸
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02484664
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.